Drugs / DL-alpha-tocopherol
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT00114387 | Jul 1996 → Sep 2000 | atherosclerosis | National Institute on Aging (NIA) | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT00235716 | Aug 2007 → Sep 2012 | Alzheimer disease | US Department of Veterans Affairs | Completed | Mixed |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DL-alpha-tocopherol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00114387 ↗ |
| Known as | vitamin E | “The purpose of this study is to examine whether vitamin E (DL-alpha-tocopherol) supplementation will reduce the progression of early atherosclerosis” NCT00114387 ↗ |
| Route | Oral | “Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening).” NCT00235716 ↗ |